Improving testing for hepatitis B before treatment with rituximab

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 10, 2016, Pages 1172-1178

  Dyson, Jessica K ^a,c   Jopson, Laura ^a   Ng, Sarah ^a   Lowery, Matthew ^b   Harwood, Jayne ^b   Waugh, Sheila ^b   Valappil, Manoj ^b,e   McPherson, Stuart ^a,d  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e Public Health Laboratory   (United Kingdom)

Author keywords

hepatitis B; immunosuppression; reactivation; rituximab; screening

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PROTOCOL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MULTIPLE CYCLE TREATMENT; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CLINICAL PRACTICE; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IN SERVICE TRAINING; MIDDLE AGED; PREDICTIVE VALUE; PROGRAM EVALUATION; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; EDUCATION, MEDICAL, CONTINUING; FEMALE; GUIDELINE ADHERENCE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INSERVICE TRAINING; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84978066129     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000689     Document Type: Article

References (43)

1. WHO. Hepatitis B factsheet. Available at: Http://www.who.int/media centre/factsheets/fs204/en/. [Accessed 8 November 2015].
2. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010; 340:b5429.
3. Centers for Disease Control and Prevention. Travelers' health; yellow book. Atlanta, GA: Services UDoHaH; 2008.
4. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: The prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010; 17:327-335.
5. McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, et al. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. J Viral Hepat 2013; 20:638-644.
6. National Institute for Health and Care Clinical Excellence (NICE). Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults; 2013. Available at: Guidance.nice. org.uk/cg165. [Accessed 8 November 2015].
7. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
8. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR [online serial]. 2008; 57:RR-8. Available at: Http://www.cdc.gov/mmwr/pdf/rr/rr5708.pdf. [Accessed 8 November 2015].
9. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: Current practice and opportunities for improvement. Curr Oncol 2010; 17:32-38.
10. Wi CI, Loo NM, Larson JJ, Moynihan TJ, Madde NR, Grendahl DC, et al. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroenterol Hepatol 2015; 13:970-975. quiz e51.
11. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez- Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013; 13:534.
12. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215-219. quiz e16-e17.
13. Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis- B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003; 18:849-854.
14. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-188.
15. Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: Risk factors and survival. Chin J Cancer 2015; 34:225-234.
16. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study. J Clin Oncol 2014; 32:3736-3743.
17. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl 1):107-109.
18. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925-2930.
19. FDA Prescribing Information. Label information for rituximab. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/103705s5367 s5388lbl.pdf. [Accessed 8 November 2015].
20. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximabassociated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31:2765-2772.
21. Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int 2015; 9:224-230.
22. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA 2014; 312:2521-2530.
23. Dyson JK, Hudson M, McPherson S. Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clin Med (Lond) 2014; 14:551-555.
24. Standards for microbiology investigations. Available at: Https://www. gov.uk/government/collections/standards-for-microbiology-investigatio ns-smi. [Accessed 14 February 2016].
25. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113:3147-3153.
26. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447-449.
27. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008; 47:844-853.
28. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148:519-528.
29. Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Gesme DH, Jacobson JO, et al. A process for measuring the quality of cancer care: The Quality Oncology Practice Initiative. J Clin Oncol 2005; 23: 6233-6239.
30. Sun WC, Hsu PI, Yu HC, Lin KH, Tsay FW, Wang HM, et al. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One 2015; 10: E0116978.
31. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10: 1412-1415.
32. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: A costeffectiveness analysis. J Clin Oncol 2012; 30:3167-3173.
33. Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:463-468.
34. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
35. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104-1108.
36. Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 2007; 86:639-645.
37. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611.
38. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90:13-23.
39. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22:1170-1180.
40. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924-2930.
41. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non- Hodgkin's lymphoma. Ann Hematol 2004; 83:58-60.
42. European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommendations on signals. EMAPRAC (PRAC); 2016. Available at: Http://www.ema.europa.eu/docs/en-GB/Document-library/PRAC-recommendation-on-signal/2016/04/WC500204264.pdf. [Accessed 14 February 2015].
43. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw 2011; 9:465-477.